Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen

AIDS Research and Human Retroviruses

Volumn 16, Issue 6, 2000, Pages 539-547

  Maino, Vernon C ^a   Suni, Maria A ^a   Wormsley, Susan B ^a   Carlo, Dennis J ^b   Wallace, Mark R ^c   Moss, Ronald B ^b  

^a BD Technologies   (United States)

^b Orchestra Therapeutics Inc   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHRONIC DISEASE; FLOW CYTOMETRY; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034630166     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308954     Document Type: Article

References (28)

1. Chun T-W, Carruth L, Finzi D, Shen X, DiGiuseepe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo T-H, Brookmeye R, Zelger MA, Barditch-Crovo P, and Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1997;387:183-188.
2. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD, Guo Y, Duran M, Hurley A, Tsay J, Huang YC, and Wang CC: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340(21):1605-1613.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, and Weber R: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353(9156):8 63-868.
4. Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, and Lange JMA: Outcome and predictors of failure of highly active antiretroviral therapy: One year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790-798.
5. Rinaldo CR Jr, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, and Mellors JW: Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999;179(2):329-336.
6. Lederman MM, Connick E, Landay A, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178(1):70-79.
7. Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, Pham B, Sun E, Leonard JM, and Cameron DW: Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177(4):898-904.
8. Kelleher AD, Carr A, Zaunders J, and Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-329.
9. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, and Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
10. Rosenberg E-S, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
11. Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, Birx D, Farzedagen H, Margolick J, Quinn T, et al.: AIDS Res Hum Retroviruses 1994;12:1703-1711.
12. Haas G, Hosmalin A, Hadida F, Duntze J, Debre P, and Autran B: Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors. Immunol Lett 1997;57:63-68.
13. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, and Lori F: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340(21):1683-1684.
14. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, and Picker LJ: HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 1999;5(5):518-525.
15. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, and Maino VC: Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-1419.
16. Getchell JP, Hicks DR, Svinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, and McCormick JB: Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis 1987;156:833-837.
17. Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, and Poiesz BJ: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses 1997;13:357-361.
18. LoGrippo GA: Investigations of the use of beta-propiolactone in virus inactivation. Ann NY Acad Sci 1960;83:578-594.
19. Kitchen AD, Harrison JF, and Zuckerman AJ: Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox Sang 1989;56:223-229.
20. Waldrop SL, Pichter CJ, Peterson DM, Maino VC, and Picker LJ: Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997;99:1739-1750.
21. Suni MA, Picker LJ, and Maino VC: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.
22. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, and Klausner RD: Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ER. Cell 1989;56:801-813.
23. Waldrop SL, Davis KA, Maino VC, and Picker LJ: Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 1998;161:5284-5295.
24. Andersson J, Fehniger TE, Patterson BK, Pottage J, Agnoli M, Jones P, Behbahani H, and Landay A. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998;12:F123-F129.
25. TM). J Infect Dis 1999;180:641-648.
26. Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, and Carlo DJ: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:343-350.
27. Plana M, Garcia F, Gallart T, Miro JM, and Gatell JM: Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998;352(9135):1194-1195.
28. Trauger TJ, Ferre F, Daigle AE, Jensen FC, Moss RB, Mueller SH, Richieri SP, Slade HB, and Carlo DJ: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994;169:1256-1264.